PAF C-16-d4
(Synonyms: PAF C-16-d4) 目录号 : GC47855An internal standard for the quantification of PAF C-16
Cas No.:211106-54-6
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
PAF C-
1.Prescott, S.M., Zimmerman, G.A., and McIntyre, T.M.Platelet-activating factorThe Journal of Biological Chemisty26517381-17384(1990) 2.Carolan, E.J., and Casale, T.B.Degree of platelet activating factor-induced neutrophil migration is dependent upon the molecular speciesJournal of Immunology1452561-2565(1990) 3.Rouis, M., Nigon, F., and Chapman, M.J.Platelet activating factor is a potent stimulant of the production of active oxygen species by human monocyte-derived macrophagesBiochemical and Biophysical Research Communications1561293-1301(1988) 4.Thivierge, M., and Rola-Pleszczynski, M.Platelet-activating factor enhances interleukin-6 production by alveolar macrophagesJournal of Allergy and Clinical Immunology90796-802(1992) 5.Stewart, A.G., and Grigoriadis, G.Structure-activity relationships for platelet-activating factor (PAF) and analogs reveal differences between PAF receptors on platelets and macrophagesJournal of Lipid Mediators4299-308(1991) 6.Wang, H., Tan, X.D., Qu, X.W., et al.Platelet-activating factor (PAF) up-regulates plasma and tissue PAF-acetylhydrolase activity in the rat: Effect of cycloheximidePediatric Research42597-603(1997) 7.Sturk, A., Wouter Ten Cate, J., Hosford, D., et al.The synthesis, catabolism, and pathophysiological role of platelet-activating factorAdvances in Lipid Research23219-276(1989)
Cas No. | 211106-54-6 | SDF | |
别名 | PAF C-16-d4 | ||
Canonical SMILES | CCCCCCCCCCCCCCCCOC[C@H](COP(=O)(O)OCC[N](C)(C)C)OC(=O)C | ||
分子式 | C26H50D4NO7P | 分子量 | 527.7 |
溶解度 | DMF: 10 mg/ml,DMSO: 10 mg/ml,Ethanol: 10 mg/ml,PBS pH 7.2: 25 mg/ml,Water: 30 mg/ml | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.895 mL | 9.4751 mL | 18.9502 mL |
5 mM | 0.379 mL | 1.895 mL | 3.79 mL |
10 mM | 0.1895 mL | 0.9475 mL | 1.895 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。